American Society for Quality (www.asq.org) – Washington D.C. and Maryland Metro, Section 509 (www.asq509.org)

Biomed/Biotech Special Interest Group (SIG) Meeting

“Advances in Development of Pneumococcal Vaccines”

To be presented by

Don Chen, PhD
(donchen@synamvaccine.com)
Founder & President/CEO, SynAm Vaccine

Thursday, October 11, 2012

6:00 – 6:20 PM – Networking; Pizza/drink
6:20 – 8:30 PM – Program
8:30 – 8:45 PM – Door-prizes drawing; Networking

Online Registration site: http://www.asq509.org/ht/d/DoSurvey/i/35817

Open to Public –
$5: non-ASQ members to cover pizza/drink cost;
Free: ASQ Members, veterans, senior citizens, students, interns, residents, postdocs, FDA Commissioner’s Fellows, and current job-seekers

Location: Kelly’s Deli Conference Center, 7519 Standish Place, Rockville, MD 20855
Registration Deadline: Please register by Thursday noon, October 11, 2012.
Question: Please contact Dr. C.J. George Chang, Chair of Biomed/Biotech SIG, ASQ509; gchang2008@yahoo.com or 240-793-8425 (cell).

Driving directions: By Car: From I-270 (N or S bound): Take Exit 9A and exit from the FIRST right exit; turn left (east) onto Shady Grove Dr.; turn right (south) onto Rockville Pike (Route 355); turn left (east) onto East Gude Dr.; turn left (north) immediately onto Crabb’s Branch Dr.; turn left (west) immediately onto Standish Place. The first building on your right side is 7519 Standish Place; open parking). The venue is on the first floor with its entrance opposite to the left side of building main entrance. By Metro train: Off from Red Line Shady Grove Station, and take RideOn Route 59 TOWARD ROCKVILLE and get off from “Calhoun Place” stop. Standish Place is next to the Bus stop. Our venue is within 2 min of walking distance from the stop.
Summary:

Based on the long history of existence of *Streptococcus pneumoniae*, a silent killer and the bacteria that causes pneumococcal diseases, we will review the literature to appreciate how science has progressed in this area and how the industry has struggled to come up with a safe and effective vaccine to eradicate the pneumococcus.

We will also examine the contribution of numerous scientists in this area in the last 130 years and will discuss in a quality assurance exercise format, possible solutions for next generation vaccines, manufacturing compliance of current vaccines on the market, and introduce current research and results.

Presenter’s Bio: Don Chen, PhD

Don Chen received his PhD in Pharmacology/Toxicology from the University of Kansas Medical Center, Kansas City, Kansas. He was a NIH Postgraduate Fellow at the Mayo Clinic, working in the renovascular hypertension group focusing on the role of the rennin-angiotensin-bradykinin system and cardiopulmonary reflex in hypertension.

Don served as a group leader at Novartis in the preclinical and early phase I/II clinical research and development for angiotensin converting enzyme (ACE) inhibitors as a new antihypertensive agent, cultivating in the commercialization of a new FDA-approved drug for hypertension. He worked as a reviewer for the US FDA in the Division of Cardio-Renal Drug Review and later became the first Expert Reviewer in Pharmacology/Toxicology. He has served as an Expert Consultant for FDA and for a CRO - Biometric Research Institute, later acquired by Quintiles - in preclinical and early clinical Phase I/II areas in drugs, biologics and medical devices.

Dr. Chen is the founder of SynAm Vaccine and has been developing universal pneumococcal vaccines since 2000.